A mechanistic insight into the biological activities of urolithins as gut microbial metabolites of ellagitannins. (20th September 2021)

• Record Type: Journal Article
• Authors: Hasheminezhad, Seyyed Hossein; Boozari, Motahareh; Iranshahi, Mehrdad; Yazarlu, Omid; Sahebkar, Amirhossein; Hasanpour, Maede; Iranshahy, Milad
• Is Part Of: Phytotherapy research. Volume 36:Number 1(2022)
• Page Start: 112
• Page End: 146
• Publication Date: 2021-09-20
• Subjects: Antiaging -- Cancer -- Inflammation -- Mitophagy -- Urolithin; Materia medica, Vegetable -- Periodicals; Botany, Medical -- Periodicals; Medicinal plants -- Periodicals; Plant Extracts -- therapeutic use -- Periodicals; Plants, Medicinal -- Periodicals; 581.634
• DOI: 10.1002/ptr.7290
• Languages: English
• ISSNs: 0951-418X

Abstract

Abstract : Urolithins are the gut metabolites produced from ellagitannin‐rich foods such as pomegranates, tea, walnuts, as well as strawberries, raspberries, blackberries, and cloudberries. Urolithins are of growing interest due to their various biological activities including cardiovascular protection, anti‐inflammatory activity, anticancer properties, antidiabetic activity, and antiaging properties. Several studies mostly based on in vitro and in vivo experiments have investigated the potential mechanisms of urolithins which support the beneficial effects of urolithins in the treatment of several diseases such as Alzheimer's disease, type 2 diabetes mellitus, liver disease, cardiovascular disease, and various cancers. It is now obvious that urolithins can involve several cellular mechanisms including inhibition of MDM2‐p53 interaction, modulation of mitogen‐activated protein kinase pathway, and suppressing nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) activity. Antiaging activity is the most appealing and probably the most important property of urolithin A that has been investigated in depth in recent studies, owing to its unique effects on activation of mitophagy and mitochondrial biogenesis. A recent clinical trial showed that urolithin A is safe up to 2, 500 mg/day and can improve mitochondrial biomarkers in elderly patients. Regarding the importance of mitochondria in the pathophysiology of many diseases, urolithins merit further research especially in clinical trials to unravel more aspects of their clinical significance. Besides the nutritional value of urolithins, recent studies proved that urolithins can be used as pharmacological agents to prevent or cure several diseases. Here, we comprehensively review the potential role of urolithins as new therapeutic agents with a special focus on the molecular pathways that have been involved in their biological effects. The pharmacokinetics of urolithins is also included.